| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 259 | 2024 | 1406 | 25.170 |
Why?
|
| Brain | 194 | 2024 | 1241 | 15.260 |
Why?
|
| Aging | 118 | 2023 | 1175 | 10.860 |
Why?
|
| Cognitive Dysfunction | 83 | 2023 | 803 | 10.220 |
Why?
|
| Dementia | 55 | 2023 | 415 | 8.170 |
Why?
|
| TDP-43 Proteinopathies | 23 | 2023 | 87 | 7.810 |
Why?
|
| Aged, 80 and over | 264 | 2024 | 3857 | 7.420 |
Why?
|
| Cognition Disorders | 76 | 2023 | 724 | 6.920 |
Why?
|
| Cerebrovascular Disorders | 23 | 2023 | 104 | 5.930 |
Why?
|
| Cognition | 70 | 2024 | 1025 | 5.680 |
Why?
|
| Humans | 418 | 2024 | 23156 | 5.430 |
Why?
|
| Aged | 254 | 2024 | 7638 | 5.290 |
Why?
|
| DNA-Binding Proteins | 35 | 2023 | 231 | 5.170 |
Why?
|
| Amyloid beta-Peptides | 64 | 2024 | 210 | 5.140 |
Why?
|
| Cerebral Amyloid Angiopathy | 26 | 2023 | 96 | 5.060 |
Why?
|
| Male | 293 | 2024 | 12636 | 5.000 |
Why?
|
| Female | 291 | 2024 | 13117 | 4.930 |
Why?
|
| Frontotemporal Lobar Degeneration | 11 | 2023 | 22 | 4.010 |
Why?
|
| Lewy Body Disease | 20 | 2022 | 74 | 3.880 |
Why?
|
| Cohort Studies | 96 | 2024 | 1463 | 3.760 |
Why?
|
| Lewy Bodies | 31 | 2023 | 151 | 3.460 |
Why?
|
| Cerebral Infarction | 28 | 2020 | 113 | 3.130 |
Why?
|
| Genetic Predisposition to Disease | 31 | 2022 | 277 | 2.910 |
Why?
|
| Longitudinal Studies | 81 | 2023 | 1103 | 2.850 |
Why?
|
| tau Proteins | 41 | 2023 | 153 | 2.780 |
Why?
|
| Neuropsychological Tests | 70 | 2022 | 916 | 2.720 |
Why?
|
| Parkinsonian Disorders | 13 | 2023 | 170 | 2.600 |
Why?
|
| Neurofibrillary Tangles | 38 | 2023 | 121 | 2.510 |
Why?
|
| Apolipoproteins E | 27 | 2023 | 160 | 2.480 |
Why?
|
| Hippocampus | 21 | 2022 | 196 | 2.480 |
Why?
|
| Autopsy | 55 | 2023 | 260 | 2.350 |
Why?
|
| Plaque, Amyloid | 33 | 2023 | 90 | 2.350 |
Why?
|
| Nervous System Diseases | 12 | 2023 | 101 | 2.340 |
Why?
|
| Arteriolosclerosis | 12 | 2023 | 61 | 2.250 |
Why?
|
| Neurodegenerative Diseases | 11 | 2023 | 98 | 2.240 |
Why?
|
| Apolipoprotein E4 | 24 | 2023 | 184 | 2.240 |
Why?
|
| Nerve Tissue Proteins | 14 | 2022 | 116 | 2.100 |
Why?
|
| Parkinson Disease | 16 | 2023 | 595 | 1.990 |
Why?
|
| Memory | 19 | 2020 | 223 | 1.950 |
Why?
|
| Brain Infarction | 12 | 2020 | 63 | 1.920 |
Why?
|
| Cerebral Small Vessel Diseases | 4 | 2023 | 10 | 1.890 |
Why?
|
| White Matter | 13 | 2023 | 113 | 1.870 |
Why?
|
| Independent Living | 18 | 2023 | 240 | 1.870 |
Why?
|
| Cerebral Cortex | 11 | 2021 | 128 | 1.820 |
Why?
|
| Diet, Mediterranean | 5 | 2023 | 72 | 1.800 |
Why?
|
| Membrane Proteins | 12 | 2022 | 140 | 1.760 |
Why?
|
| Hypertension | 5 | 2023 | 169 | 1.700 |
Why?
|
| Intracranial Arteriosclerosis | 12 | 2022 | 41 | 1.590 |
Why?
|
| Magnetic Resonance Imaging | 32 | 2023 | 871 | 1.590 |
Why?
|
| Limbic Encephalitis | 3 | 2023 | 10 | 1.560 |
Why?
|
| Genome-Wide Association Study | 29 | 2022 | 160 | 1.540 |
Why?
|
| Genotype | 30 | 2023 | 265 | 1.530 |
Why?
|
| Amyotrophic Lateral Sclerosis | 3 | 2023 | 21 | 1.520 |
Why?
|
| Cognitive Aging | 8 | 2021 | 64 | 1.510 |
Why?
|
| Memory Disorders | 10 | 2018 | 115 | 1.500 |
Why?
|
| Polymorphism, Single Nucleotide | 24 | 2022 | 176 | 1.500 |
Why?
|
| Neuropathology | 14 | 2023 | 63 | 1.420 |
Why?
|
| Genetic Loci | 7 | 2019 | 31 | 1.400 |
Why?
|
| Brain Diseases | 7 | 2021 | 56 | 1.360 |
Why?
|
| Risk Factors | 48 | 2023 | 2019 | 1.350 |
Why?
|
| Atherosclerosis | 4 | 2023 | 47 | 1.320 |
Why?
|
| Dementia, Vascular | 7 | 2023 | 36 | 1.300 |
Why?
|
| Sex Characteristics | 7 | 2023 | 91 | 1.220 |
Why?
|
| Microglia | 15 | 2021 | 108 | 1.190 |
Why?
|
| Temporal Lobe | 10 | 2020 | 57 | 1.190 |
Why?
|
| Biomarkers | 19 | 2023 | 481 | 1.150 |
Why?
|
| Disease Progression | 22 | 2022 | 543 | 1.140 |
Why?
|
| Neurons | 17 | 2022 | 273 | 1.140 |
Why?
|
| Frontotemporal Dementia | 3 | 2023 | 11 | 1.140 |
Why?
|
| Motor Disorders | 3 | 2023 | 18 | 1.100 |
Why?
|
| Prospective Studies | 31 | 2023 | 1511 | 1.090 |
Why?
|
| Brain Injuries, Traumatic | 4 | 2022 | 15 | 1.060 |
Why?
|
| Amyloid | 10 | 2021 | 38 | 1.050 |
Why?
|
| Proteomics | 11 | 2023 | 58 | 1.050 |
Why?
|
| Follow-Up Studies | 28 | 2021 | 1430 | 1.030 |
Why?
|
| alpha-Synuclein | 8 | 2020 | 103 | 1.020 |
Why?
|
| Tauopathies | 7 | 2023 | 14 | 1.020 |
Why?
|
| Hospitalization | 2 | 2019 | 287 | 1.010 |
Why?
|
| Genetic Association Studies | 11 | 2020 | 58 | 0.930 |
Why?
|
| DNA Methylation | 11 | 2021 | 129 | 0.930 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2020 | 46 | 0.920 |
Why?
|
| Memory, Episodic | 10 | 2023 | 81 | 0.900 |
Why?
|
| Cerebrovascular Circulation | 3 | 2022 | 28 | 0.870 |
Why?
|
| Geriatric Assessment | 7 | 2017 | 171 | 0.860 |
Why?
|
| Spinal Cord | 5 | 2022 | 74 | 0.860 |
Why?
|
| Transcriptome | 7 | 2022 | 53 | 0.850 |
Why?
|
| United States | 24 | 2021 | 1796 | 0.820 |
Why?
|
| Age Factors | 17 | 2021 | 650 | 0.790 |
Why?
|
| Cytomegalovirus Infections | 2 | 2013 | 29 | 0.780 |
Why?
|
| Prefrontal Cortex | 8 | 2021 | 104 | 0.770 |
Why?
|
| Sclerosis | 12 | 2022 | 54 | 0.750 |
Why?
|
| Blood Pressure | 3 | 2020 | 171 | 0.740 |
Why?
|
| Cognitive Reserve | 5 | 2022 | 24 | 0.740 |
Why?
|
| Middle Aged | 42 | 2022 | 7964 | 0.740 |
Why?
|
| Frontal Lobe | 10 | 2022 | 57 | 0.730 |
Why?
|
| Substantia Nigra | 5 | 2021 | 102 | 0.670 |
Why?
|
| Genetic Variation | 8 | 2021 | 71 | 0.670 |
Why?
|
| Neuroimaging | 10 | 2021 | 105 | 0.660 |
Why?
|
| Aniline Compounds | 9 | 2017 | 30 | 0.660 |
Why?
|
| Educational Status | 10 | 2023 | 223 | 0.660 |
Why?
|
| Brain Chemistry | 6 | 2021 | 33 | 0.640 |
Why?
|
| Alleles | 15 | 2023 | 172 | 0.630 |
Why?
|
| Ethylene Glycols | 7 | 2017 | 7 | 0.620 |
Why?
|
| Animals | 28 | 2022 | 3270 | 0.620 |
Why?
|
| Neurology | 1 | 2020 | 35 | 0.600 |
Why?
|
| Synapses | 4 | 2021 | 23 | 0.590 |
Why?
|
| Epigenesis, Genetic | 5 | 2021 | 60 | 0.590 |
Why?
|
| Gene Expression | 8 | 2019 | 180 | 0.590 |
Why?
|
| Cerebral Arteries | 3 | 2016 | 21 | 0.580 |
Why?
|
| Emergencies | 1 | 2019 | 28 | 0.580 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2021 | 25 | 0.570 |
Why?
|
| Severity of Illness Index | 15 | 2021 | 804 | 0.570 |
Why?
|
| Phenotype | 11 | 2021 | 260 | 0.570 |
Why?
|
| Linear Models | 13 | 2020 | 202 | 0.560 |
Why?
|
| Folic Acid | 4 | 2006 | 21 | 0.550 |
Why?
|
| Polymorphism, Genetic | 4 | 2017 | 48 | 0.540 |
Why?
|
| Exercise | 6 | 2021 | 404 | 0.530 |
Why?
|
| Dietary Supplements | 3 | 2006 | 55 | 0.530 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 295 | 0.530 |
Why?
|
| Cross-Sectional Studies | 11 | 2022 | 775 | 0.520 |
Why?
|
| Mutation | 7 | 2022 | 329 | 0.520 |
Why?
|
| Receptors, Immunologic | 4 | 2020 | 14 | 0.520 |
Why?
|
| Motor Activity | 5 | 2019 | 274 | 0.510 |
Why?
|
| Membrane Glycoproteins | 4 | 2020 | 49 | 0.510 |
Why?
|
| Logistic Models | 12 | 2019 | 356 | 0.510 |
Why?
|
| Biomedical Research | 2 | 2021 | 51 | 0.510 |
Why?
|
| Positron-Emission Tomography | 8 | 2023 | 75 | 0.490 |
Why?
|
| Comorbidity | 12 | 2021 | 429 | 0.480 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2016 | 273 | 0.480 |
Why?
|
| Olfaction Disorders | 4 | 2021 | 38 | 0.470 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 8 | 0.460 |
Why?
|
| SNARE Proteins | 3 | 2021 | 9 | 0.460 |
Why?
|
| Stroke | 4 | 2023 | 243 | 0.460 |
Why?
|
| Psychomotor Performance | 6 | 2021 | 162 | 0.460 |
Why?
|
| Atrophy | 6 | 2021 | 65 | 0.440 |
Why?
|
| Infarction | 3 | 2023 | 21 | 0.430 |
Why?
|
| Tissue Donors | 2 | 2012 | 67 | 0.430 |
Why?
|
| Apolipoprotein E2 | 3 | 2023 | 7 | 0.410 |
Why?
|
| Neocortex | 4 | 2019 | 23 | 0.410 |
Why?
|
| Social Behavior | 1 | 2013 | 54 | 0.400 |
Why?
|
| Peptide Fragments | 5 | 2018 | 59 | 0.400 |
Why?
|
| Adult | 16 | 2023 | 6942 | 0.380 |
Why?
|
| Cerebral Hemorrhage | 4 | 2023 | 104 | 0.380 |
Why?
|
| Sequence Analysis, RNA | 7 | 2020 | 25 | 0.380 |
Why?
|
| Neuropeptides | 3 | 2023 | 22 | 0.380 |
Why?
|
| Genome, Human | 3 | 2018 | 34 | 0.370 |
Why?
|
| Life Style | 1 | 2013 | 167 | 0.370 |
Why?
|
| Dietary Approaches To Stop Hypertension | 2 | 2023 | 26 | 0.370 |
Why?
|
| Nuclear Proteins | 4 | 2017 | 73 | 0.370 |
Why?
|
| Membrane Transport Proteins | 5 | 2022 | 42 | 0.360 |
Why?
|
| Apoptosis | 1 | 2012 | 194 | 0.350 |
Why?
|
| Antibodies, Antiphospholipid | 3 | 2019 | 20 | 0.350 |
Why?
|
| Immunohistochemistry | 10 | 2020 | 338 | 0.350 |
Why?
|
| Nanomedicine | 1 | 2011 | 1 | 0.350 |
Why?
|
| Diabetes Mellitus | 5 | 2021 | 107 | 0.340 |
Why?
|
| Patient Selection | 1 | 2012 | 170 | 0.340 |
Why?
|
| Residence Characteristics | 7 | 2018 | 179 | 0.340 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 3 | 2019 | 21 | 0.340 |
Why?
|
| Circadian Rhythm | 3 | 2021 | 213 | 0.330 |
Why?
|
| Case-Control Studies | 10 | 2019 | 485 | 0.320 |
Why?
|
| National Institute on Aging (U.S.) | 6 | 2019 | 10 | 0.320 |
Why?
|
| Iron | 2 | 2021 | 14 | 0.320 |
Why?
|
| Amygdala | 2 | 2021 | 35 | 0.310 |
Why?
|
| Chicago | 8 | 2021 | 847 | 0.310 |
Why?
|
| Vitamin B Complex | 2 | 2006 | 6 | 0.310 |
Why?
|
| Surveys and Questionnaires | 9 | 2023 | 1036 | 0.310 |
Why?
|
| Algorithms | 4 | 2020 | 304 | 0.300 |
Why?
|
| Heterozygote | 4 | 2018 | 90 | 0.300 |
Why?
|
| Sleep Deprivation | 3 | 2019 | 35 | 0.300 |
Why?
|
| Transcription Factors | 2 | 2021 | 149 | 0.300 |
Why?
|
| Vascular Diseases | 3 | 2019 | 34 | 0.290 |
Why?
|
| Vitamin B 12 | 2 | 2006 | 13 | 0.290 |
Why?
|
| Neoplasms | 1 | 2011 | 218 | 0.290 |
Why?
|
| Community Health Services | 1 | 2009 | 27 | 0.290 |
Why?
|
| Sulfonylurea Receptors | 2 | 2021 | 2 | 0.280 |
Why?
|
| Medicare | 2 | 2019 | 108 | 0.280 |
Why?
|
| Haplotypes | 5 | 2020 | 43 | 0.280 |
Why?
|
| Microvessels | 2 | 2019 | 12 | 0.280 |
Why?
|
| Memory, Short-Term | 3 | 2022 | 81 | 0.280 |
Why?
|
| Frail Elderly | 3 | 2014 | 37 | 0.270 |
Why?
|
| Stress, Psychological | 4 | 2012 | 215 | 0.270 |
Why?
|
| Housing for the Elderly | 1 | 2007 | 6 | 0.260 |
Why?
|
| Health Literacy | 2 | 2020 | 87 | 0.260 |
Why?
|
| Inflammation | 3 | 2019 | 230 | 0.260 |
Why?
|
| gamma-Tocopherol | 2 | 2020 | 8 | 0.260 |
Why?
|
| Awareness | 2 | 2019 | 40 | 0.260 |
Why?
|
| Religious Personnel | 2 | 2018 | 9 | 0.260 |
Why?
|
| Sleep Wake Disorders | 3 | 2019 | 110 | 0.260 |
Why?
|
| Movement Disorders | 2 | 2021 | 57 | 0.260 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 109 | 0.260 |
Why?
|
| Insulin Resistance | 2 | 2021 | 48 | 0.260 |
Why?
|
| Postmortem Changes | 5 | 2016 | 22 | 0.260 |
Why?
|
| Copper | 2 | 2022 | 15 | 0.250 |
Why?
|
| Gene Expression Regulation | 5 | 2020 | 226 | 0.250 |
Why?
|
| Amyloidosis | 3 | 2022 | 12 | 0.250 |
Why?
|
| Brain Mapping | 5 | 2022 | 124 | 0.250 |
Why?
|
| Interneurons | 1 | 2006 | 3 | 0.250 |
Why?
|
| Entorhinal Cortex | 1 | 2006 | 17 | 0.240 |
Why?
|
| Research Design | 4 | 2012 | 162 | 0.240 |
Why?
|
| Urinary Incontinence | 2 | 2017 | 21 | 0.240 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2017 | 36 | 0.240 |
Why?
|
| Odds Ratio | 7 | 2017 | 227 | 0.240 |
Why?
|
| Mice | 10 | 2022 | 1238 | 0.240 |
Why?
|
| LDL-Receptor Related Proteins | 4 | 2022 | 9 | 0.240 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 3 | 2015 | 5 | 0.240 |
Why?
|
| Presynaptic Terminals | 3 | 2023 | 8 | 0.240 |
Why?
|
| Time Factors | 6 | 2021 | 1264 | 0.240 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2023 | 70 | 0.240 |
Why?
|
| Proteome | 3 | 2023 | 23 | 0.240 |
Why?
|
| Gray Matter | 3 | 2020 | 43 | 0.230 |
Why?
|
| Models, Statistical | 4 | 2013 | 116 | 0.230 |
Why?
|
| Food, Fortified | 1 | 2005 | 8 | 0.230 |
Why?
|
| Gene Frequency | 4 | 2017 | 42 | 0.230 |
Why?
|
| Insulin | 3 | 2021 | 77 | 0.220 |
Why?
|
| Databases, Factual | 4 | 2020 | 310 | 0.220 |
Why?
|
| Phosphorylation | 7 | 2021 | 130 | 0.220 |
Why?
|
| Antihypertensive Agents | 2 | 2019 | 42 | 0.220 |
Why?
|
| Mice, Transgenic | 7 | 2022 | 175 | 0.220 |
Why?
|
| Diagnosis | 4 | 2018 | 18 | 0.220 |
Why?
|
| Incidence | 10 | 2019 | 631 | 0.210 |
Why?
|
| Fluorine Radioisotopes | 2 | 2014 | 5 | 0.210 |
Why?
|
| Vitamin D | 2 | 2022 | 28 | 0.210 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2006 | 120 | 0.210 |
Why?
|
| Sleep | 3 | 2019 | 270 | 0.210 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 3 | 2021 | 35 | 0.210 |
Why?
|
| Mental Status Schedule | 4 | 2018 | 72 | 0.210 |
Why?
|
| Multiple Sclerosis | 2 | 2022 | 77 | 0.210 |
Why?
|
| DNA | 2 | 2005 | 94 | 0.200 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 39 | 0.200 |
Why?
|
| Microcirculation | 4 | 2018 | 26 | 0.200 |
Why?
|
| Resilience, Psychological | 1 | 2023 | 20 | 0.200 |
Why?
|
| Blood-Brain Barrier | 4 | 2019 | 34 | 0.200 |
Why?
|
| Depression | 5 | 2021 | 383 | 0.200 |
Why?
|
| Rest | 2 | 2021 | 28 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 3 | 2015 | 235 | 0.200 |
Why?
|
| Organ Size | 4 | 2019 | 86 | 0.200 |
Why?
|
| Locus Coeruleus | 2 | 2013 | 16 | 0.190 |
Why?
|
| Lymphatic Vessels | 1 | 2022 | 8 | 0.190 |
Why?
|
| Insulins | 1 | 2022 | 3 | 0.190 |
Why?
|
| Flavonols | 1 | 2022 | 6 | 0.190 |
Why?
|
| Parietal Lobe | 2 | 2021 | 9 | 0.190 |
Why?
|
| Statistics as Topic | 6 | 2017 | 85 | 0.190 |
Why?
|
| Societies | 2 | 2020 | 5 | 0.190 |
Why?
|
| Anxiety | 3 | 2013 | 143 | 0.190 |
Why?
|
| Exonucleases | 1 | 2022 | 1 | 0.190 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2019 | 14 | 0.190 |
Why?
|
| Bone Marrow | 1 | 2022 | 61 | 0.190 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 192 | 0.190 |
Why?
|
| Fatty Acids | 3 | 2018 | 33 | 0.180 |
Why?
|
| Unconsciousness | 1 | 2022 | 6 | 0.180 |
Why?
|
| Actigraphy | 6 | 2021 | 81 | 0.180 |
Why?
|
| Arterioles | 3 | 2020 | 11 | 0.180 |
Why?
|
| Anthocyanins | 1 | 2022 | 5 | 0.180 |
Why?
|
| Fruit | 1 | 2022 | 24 | 0.180 |
Why?
|
| Interdisciplinary Communication | 1 | 2021 | 16 | 0.180 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2021 | 1 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2021 | 1 | 0.180 |
Why?
|
| Mental Recall | 2 | 2020 | 49 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 164 | 0.180 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2021 | 1 | 0.180 |
Why?
|
| Synapsins | 2 | 2021 | 4 | 0.180 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 168 | 0.180 |
Why?
|
| Perception | 2 | 2019 | 66 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 43 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2022 | 38 | 0.180 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 7 | 0.180 |
Why?
|
| Retrospective Studies | 5 | 2022 | 2989 | 0.180 |
Why?
|
| Cause of Death | 1 | 2021 | 56 | 0.180 |
Why?
|
| Homeodomain Proteins | 1 | 2021 | 55 | 0.170 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2019 | 46 | 0.170 |
Why?
|
| Netrins | 1 | 2021 | 1 | 0.170 |
Why?
|
| Astrocytes | 3 | 2020 | 126 | 0.170 |
Why?
|
| Phospholipase D | 1 | 2021 | 4 | 0.170 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2021 | 21 | 0.170 |
Why?
|
| Epistasis, Genetic | 2 | 2020 | 5 | 0.170 |
Why?
|
| CA2 Region, Hippocampal | 1 | 2021 | 1 | 0.170 |
Why?
|
| Radiopharmaceuticals | 2 | 2012 | 48 | 0.170 |
Why?
|
| Vitamin K | 1 | 2021 | 5 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 12 | 0.170 |
Why?
|
| Proteostasis Deficiencies | 1 | 2020 | 1 | 0.170 |
Why?
|
| RNA, Messenger | 3 | 2017 | 283 | 0.170 |
Why?
|
| Memory and Learning Tests | 1 | 2020 | 5 | 0.170 |
Why?
|
| Data Interpretation, Statistical | 2 | 2018 | 63 | 0.170 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2022 | 45 | 0.170 |
Why?
|
| Serial Learning | 1 | 2020 | 6 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 83 | 0.170 |
Why?
|
| Personality | 2 | 2013 | 42 | 0.170 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 50 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2021 | 39 | 0.170 |
Why?
|
| Peptides | 1 | 2021 | 89 | 0.170 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 30 | 0.160 |
Why?
|
| Late Onset Disorders | 1 | 2020 | 5 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2020 | 26 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 94 | 0.160 |
Why?
|
| Proteins | 1 | 2020 | 51 | 0.160 |
Why?
|
| RNA Splicing Factors | 1 | 2020 | 3 | 0.160 |
Why?
|
| Organ Specificity | 2 | 2020 | 31 | 0.160 |
Why?
|
| Mortality | 2 | 2021 | 76 | 0.160 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 5 | 0.160 |
Why?
|
| Signal Transduction | 5 | 2021 | 387 | 0.160 |
Why?
|
| Regression Analysis | 5 | 2018 | 215 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 35 | 0.160 |
Why?
|
| CpG Islands | 5 | 2021 | 43 | 0.160 |
Why?
|
| Research | 1 | 2020 | 36 | 0.160 |
Why?
|
| Homozygote | 1 | 2020 | 15 | 0.160 |
Why?
|
| Bromine | 1 | 2020 | 1 | 0.160 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 2022 | 11 | 0.160 |
Why?
|
| Amyloid Neuropathies | 1 | 2020 | 3 | 0.160 |
Why?
|
| Tuberous Sclerosis | 2 | 2017 | 12 | 0.160 |
Why?
|
| Child Development | 1 | 2020 | 67 | 0.160 |
Why?
|
| Cell Nucleus | 1 | 2020 | 70 | 0.160 |
Why?
|
| Sex Factors | 6 | 2020 | 399 | 0.160 |
Why?
|
| Illinois | 1 | 2020 | 224 | 0.150 |
Why?
|
| Neurites | 3 | 2020 | 5 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2020 | 44 | 0.150 |
Why?
|
| Olfactory Bulb | 1 | 2019 | 12 | 0.150 |
Why?
|
| Cell Count | 6 | 2021 | 72 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 11 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2019 | 2 | 0.150 |
Why?
|
| Adenylate Kinase | 1 | 2019 | 5 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 6 | 0.150 |
Why?
|
| Literacy | 1 | 2019 | 14 | 0.150 |
Why?
|
| Quality of Life | 2 | 2015 | 564 | 0.150 |
Why?
|
| Gait | 1 | 2023 | 384 | 0.150 |
Why?
|
| Fraud | 1 | 2019 | 17 | 0.150 |
Why?
|
| Decision Making | 1 | 2021 | 179 | 0.150 |
Why?
|
| Immunity | 1 | 2019 | 10 | 0.150 |
Why?
|
| Reward | 1 | 2019 | 18 | 0.150 |
Why?
|
| Prodromal Symptoms | 1 | 2019 | 13 | 0.150 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 95 | 0.150 |
Why?
|
| Motor Neurons | 1 | 2018 | 15 | 0.150 |
Why?
|
| Histones | 1 | 2018 | 28 | 0.150 |
Why?
|
| Lipids | 1 | 2019 | 46 | 0.140 |
Why?
|
| Disease Models, Animal | 5 | 2022 | 526 | 0.140 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 5 | 0.140 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 594 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2019 | 40 | 0.140 |
Why?
|
| E2F Transcription Factors | 1 | 2018 | 4 | 0.140 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2016 | 16 | 0.140 |
Why?
|
| Seasons | 1 | 2018 | 19 | 0.140 |
Why?
|
| Suprachiasmatic Nucleus | 2 | 2015 | 10 | 0.140 |
Why?
|
| Claudins | 1 | 2018 | 5 | 0.140 |
Why?
|
| Serpins | 1 | 2018 | 3 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 8 | 0.140 |
Why?
|
| Military Personnel | 1 | 2018 | 37 | 0.140 |
Why?
|
| Estradiol | 1 | 2018 | 52 | 0.140 |
Why?
|
| Muscle Proteins | 1 | 2018 | 26 | 0.140 |
Why?
|
| RNA | 4 | 2023 | 28 | 0.140 |
Why?
|
| Risk | 6 | 2019 | 166 | 0.140 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 11 | 0.140 |
Why?
|
| Movement | 1 | 2018 | 105 | 0.140 |
Why?
|
| Leukoencephalopathies | 1 | 2018 | 11 | 0.140 |
Why?
|
| Nerve Degeneration | 2 | 2020 | 34 | 0.140 |
Why?
|
| GPI-Linked Proteins | 3 | 2023 | 16 | 0.140 |
Why?
|
| Homocysteine | 1 | 2017 | 6 | 0.140 |
Why?
|
| Genetic Testing | 3 | 2019 | 47 | 0.140 |
Why?
|
| Central Nervous System | 1 | 2018 | 47 | 0.130 |
Why?
|
| Linkage Disequilibrium | 4 | 2017 | 26 | 0.130 |
Why?
|
| Diabetes Complications | 4 | 2021 | 47 | 0.130 |
Why?
|
| Learning | 1 | 2018 | 59 | 0.130 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 7 | 0.130 |
Why?
|
| RNA, Untranslated | 1 | 2017 | 2 | 0.130 |
Why?
|
| Epidemiologic Studies | 3 | 2012 | 18 | 0.130 |
Why?
|
| Inclusion Bodies | 3 | 2014 | 10 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 20 | 0.130 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2017 | 3 | 0.130 |
Why?
|
| Drosophila | 2 | 2021 | 5 | 0.130 |
Why?
|
| Quantitative Trait Loci | 4 | 2020 | 26 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2017 | 46 | 0.130 |
Why?
|
| Veterans | 1 | 2018 | 87 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 59 | 0.130 |
Why?
|
| Presenilin-1 | 2 | 2013 | 4 | 0.130 |
Why?
|
| Sensitivity and Specificity | 4 | 2023 | 444 | 0.120 |
Why?
|
| PubMed | 1 | 2016 | 5 | 0.120 |
Why?
|
| Translational Medical Research | 1 | 2016 | 1 | 0.120 |
Why?
|
| Mercury | 1 | 2016 | 9 | 0.120 |
Why?
|
| Seafood | 1 | 2016 | 9 | 0.120 |
Why?
|
| Munc18 Proteins | 1 | 2015 | 2 | 0.120 |
Why?
|
| GABAergic Neurons | 1 | 2015 | 3 | 0.120 |
Why?
|
| HIV Infections | 1 | 2020 | 437 | 0.120 |
Why?
|
| Causality | 3 | 2021 | 44 | 0.120 |
Why?
|
| Receptors, Complement 3b | 2 | 2016 | 8 | 0.120 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 11 | 0.120 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2015 | 2 | 0.120 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 2015 | 1 | 0.110 |
Why?
|
| Visceral Afferents | 1 | 2015 | 3 | 0.110 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2015 | 7 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 94 | 0.110 |
Why?
|
| Diet | 2 | 2014 | 181 | 0.110 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2015 | 3 | 0.110 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2015 | 10 | 0.110 |
Why?
|
| Antiporters | 1 | 2015 | 4 | 0.110 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 4 | 0.110 |
Why?
|
| Multiple System Atrophy | 1 | 2015 | 26 | 0.110 |
Why?
|
| Ankyrins | 1 | 2014 | 2 | 0.110 |
Why?
|
| Preoptic Area | 1 | 2014 | 5 | 0.110 |
Why?
|
| Congresses as Topic | 3 | 2021 | 30 | 0.110 |
Why?
|
| alpha-Tocopherol | 1 | 2014 | 12 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 16 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2014 | 89 | 0.100 |
Why?
|
| Child | 5 | 2020 | 1160 | 0.100 |
Why?
|
| Neurotic Disorders | 2 | 2011 | 15 | 0.100 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 279 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 32 | 0.100 |
Why?
|
| Religion | 1 | 2013 | 38 | 0.100 |
Why?
|
| Language | 1 | 2013 | 57 | 0.100 |
Why?
|
| Longevity | 1 | 2013 | 19 | 0.100 |
Why?
|
| Ubiquitin | 3 | 2008 | 29 | 0.100 |
Why?
|
| DNA Mutational Analysis | 2 | 2012 | 50 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2013 | 50 | 0.100 |
Why?
|
| Brain Stem | 1 | 2013 | 16 | 0.100 |
Why?
|
| Synucleins | 1 | 2013 | 5 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 36 | 0.100 |
Why?
|
| Monocytes | 1 | 2013 | 38 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 48 | 0.100 |
Why?
|
| Psychomotor Disorders | 1 | 2013 | 9 | 0.100 |
Why?
|
| Menopause | 1 | 2013 | 100 | 0.100 |
Why?
|
| Interferon-gamma | 1 | 2013 | 72 | 0.100 |
Why?
|
| PrPC Proteins | 1 | 2012 | 1 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2012 | 1 | 0.100 |
Why?
|
| Mental Disorders | 2 | 2011 | 134 | 0.100 |
Why?
|
| Protein Interaction Maps | 3 | 2018 | 10 | 0.100 |
Why?
|
| Amyloid Precursor Protein Secretases | 3 | 2019 | 7 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 13 | 0.100 |
Why?
|
| Glucosylceramidase | 1 | 2012 | 13 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 363 | 0.090 |
Why?
|
| Child Abuse | 1 | 2012 | 29 | 0.090 |
Why?
|
| Rats | 3 | 2021 | 623 | 0.090 |
Why?
|
| Emotions | 1 | 2012 | 69 | 0.090 |
Why?
|
| Single-Blind Method | 3 | 2020 | 88 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 152 | 0.090 |
Why?
|
| Smoking | 2 | 2020 | 163 | 0.090 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2012 | 15 | 0.090 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2012 | 26 | 0.090 |
Why?
|
| Apolipoprotein E3 | 2 | 2023 | 10 | 0.090 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 56 | 0.090 |
Why?
|
| Supranuclear Palsy, Progressive | 1 | 2011 | 21 | 0.090 |
Why?
|
| Cerebral Angiography | 1 | 2011 | 29 | 0.090 |
Why?
|
| Receptor, EphA1 | 1 | 2011 | 1 | 0.090 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 5 | 0.090 |
Why?
|
| China | 1 | 2011 | 45 | 0.090 |
Why?
|
| Peptidylprolyl Isomerase | 2 | 2010 | 4 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2012 | 117 | 0.090 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 13 | 0.090 |
Why?
|
| Genome | 1 | 2011 | 6 | 0.090 |
Why?
|
| Odorants | 2 | 2009 | 15 | 0.090 |
Why?
|
| Neuroglia | 2 | 2015 | 39 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 106 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2011 | 49 | 0.080 |
Why?
|
| Prevalence | 1 | 2012 | 380 | 0.080 |
Why?
|
| Cerebral Ventricles | 1 | 2011 | 17 | 0.080 |
Why?
|
| Maze Learning | 3 | 2016 | 12 | 0.080 |
Why?
|
| Vitamin E | 1 | 2011 | 38 | 0.080 |
Why?
|
| Motor Skills | 2 | 2021 | 38 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2021 | 228 | 0.080 |
Why?
|
| Lysosomes | 2 | 2021 | 20 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 437 | 0.080 |
Why?
|
| Young Adult | 4 | 2021 | 1654 | 0.080 |
Why?
|
| CA3 Region, Hippocampal | 1 | 2010 | 4 | 0.080 |
Why?
|
| Catholicism | 1 | 2010 | 13 | 0.080 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 15 | 0.080 |
Why?
|
| Neurologic Examination | 3 | 2020 | 82 | 0.080 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 2 | 2023 | 4 | 0.080 |
Why?
|
| Religion and Psychology | 1 | 2010 | 22 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2007 | 377 | 0.080 |
Why?
|
| Probability | 3 | 2020 | 72 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2009 | 9 | 0.080 |
Why?
|
| Formaldehyde | 1 | 2009 | 7 | 0.070 |
Why?
|
| Myelin Sheath | 2 | 2020 | 22 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2010 | 163 | 0.070 |
Why?
|
| Axons | 2 | 2020 | 24 | 0.070 |
Why?
|
| Anxiety Disorders | 1 | 2010 | 164 | 0.070 |
Why?
|
| Nerve Net | 2 | 2019 | 34 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 35 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2017 | 132 | 0.070 |
Why?
|
| Cell Line | 2 | 2019 | 242 | 0.070 |
Why?
|
| Prognosis | 3 | 2018 | 730 | 0.070 |
Why?
|
| Carbon-Nitrogen Lyases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Multifactorial Inheritance | 2 | 2018 | 12 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2008 | 4 | 0.070 |
Why?
|
| Data Collection | 2 | 2005 | 83 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2020 | 4 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2008 | 15 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 314 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 43 | 0.070 |
Why?
|
| Activities of Daily Living | 2 | 2007 | 368 | 0.070 |
Why?
|
| Agnosia | 1 | 2007 | 7 | 0.070 |
Why?
|
| Infant | 2 | 2023 | 483 | 0.070 |
Why?
|
| Hand Strength | 2 | 2023 | 49 | 0.070 |
Why?
|
| Long-Term Care | 1 | 2007 | 56 | 0.060 |
Why?
|
| Age of Onset | 3 | 2014 | 74 | 0.060 |
Why?
|
| Adolescent | 3 | 2021 | 1883 | 0.060 |
Why?
|
| Reactive Oxygen Species | 2 | 2018 | 102 | 0.060 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 4 | 0.060 |
Why?
|
| Trans Fatty Acids | 1 | 2006 | 4 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2019 | 276 | 0.060 |
Why?
|
| Loneliness | 1 | 2007 | 45 | 0.060 |
Why?
|
| Receptors, GABA | 1 | 2006 | 2 | 0.060 |
Why?
|
| NADPH Dehydrogenase | 1 | 2006 | 5 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 39 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2006 | 37 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 34 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 42 | 0.060 |
Why?
|
| Urban Health | 1 | 2006 | 18 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 35 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2018 | 33 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 73 | 0.060 |
Why?
|
| Heme Oxygenase-1 | 1 | 2005 | 4 | 0.060 |
Why?
|
| Walking | 2 | 2023 | 234 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 31 | 0.060 |
Why?
|
| Social Support | 1 | 2006 | 180 | 0.060 |
Why?
|
| Endophenotypes | 2 | 2015 | 6 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 161 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 313 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 312 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2014 | 19 | 0.050 |
Why?
|
| Psychological Tests | 2 | 2014 | 43 | 0.050 |
Why?
|
| Disease Susceptibility | 2 | 2018 | 55 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 78 | 0.050 |
Why?
|
| Workflow | 1 | 2023 | 7 | 0.050 |
Why?
|
| RNA, Small Nuclear | 1 | 2023 | 1 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2023 | 14 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2003 | 1 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Proteins | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Protein 2 | 1 | 2023 | 2 | 0.050 |
Why?
|
| Pan troglodytes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Lymphatic System | 1 | 2022 | 3 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2003 | 5 | 0.050 |
Why?
|
| Arachnoid | 1 | 2022 | 6 | 0.050 |
Why?
|
| Nerve Growth Factors | 1 | 2023 | 33 | 0.050 |
Why?
|
| Quercetin | 1 | 2022 | 6 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2013 | 41 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 15 | 0.050 |
Why?
|
| Kaempferols | 1 | 2022 | 7 | 0.050 |
Why?
|
| Executive Function | 1 | 2023 | 94 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2016 | 37 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2003 | 32 | 0.050 |
Why?
|
| Triglycerides | 1 | 2022 | 54 | 0.050 |
Why?
|
| Dura Mater | 1 | 2022 | 15 | 0.050 |
Why?
|
| Gene Dosage | 2 | 2012 | 17 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2023 | 62 | 0.050 |
Why?
|
| Cholesterol | 1 | 2022 | 57 | 0.050 |
Why?
|
| Eating | 1 | 2022 | 47 | 0.050 |
Why?
|
| Machine Learning | 1 | 2023 | 59 | 0.050 |
Why?
|
| Lumbar Vertebrae | 2 | 2018 | 354 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 47 | 0.050 |
Why?
|
| Stem Cells | 1 | 2022 | 34 | 0.050 |
Why?
|
| Zebrafish | 1 | 2022 | 16 | 0.050 |
Why?
|
| Thiazoles | 2 | 2013 | 16 | 0.050 |
Why?
|
| Self Stimulation | 1 | 2002 | 6 | 0.050 |
Why?
|
| Individuality | 1 | 2022 | 15 | 0.050 |
Why?
|
| Parahippocampal Gyrus | 1 | 2002 | 3 | 0.050 |
Why?
|
| Silver Staining | 1 | 2002 | 3 | 0.050 |
Why?
|
| Neuropil Threads | 1 | 2002 | 4 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 5 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2022 | 19 | 0.050 |
Why?
|
| Interdisciplinary Research | 1 | 2021 | 1 | 0.050 |
Why?
|
| Synaptotagmins | 1 | 2021 | 2 | 0.050 |
Why?
|
| Synaptophysin | 1 | 2021 | 7 | 0.050 |
Why?
|
| Qa-SNARE Proteins | 1 | 2021 | 5 | 0.050 |
Why?
|
| Caffeine | 1 | 2022 | 54 | 0.040 |
Why?
|
| Brazil | 1 | 2021 | 35 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2021 | 37 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2014 | 5 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 56 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2021 | 6 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 18 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2013 | 569 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 11 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2021 | 15 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2021 | 24 | 0.040 |
Why?
|
| Serotonin | 1 | 2021 | 22 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2021 | 33 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 12 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2021 | 94 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2023 | 381 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2020 | 7 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 31 | 0.040 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2020 | 4 | 0.040 |
Why?
|
| Actinin | 1 | 2020 | 7 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 8 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 8 | 0.040 |
Why?
|
| Epoxide Hydrolases | 1 | 2020 | 8 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 2 | 0.040 |
Why?
|
| Species Specificity | 1 | 2020 | 34 | 0.040 |
Why?
|
| Computational Biology | 1 | 2020 | 12 | 0.040 |
Why?
|
| Integrin alphaVbeta3 | 2 | 2011 | 15 | 0.040 |
Why?
|
| Neuropilin-1 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 2020 | 27 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2019 | 23 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 369 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2019 | 20 | 0.040 |
Why?
|
| COS Cells | 1 | 2019 | 38 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2012 | 87 | 0.040 |
Why?
|
| Protein Binding | 1 | 2019 | 112 | 0.040 |
Why?
|
| Nerve Growth Factor | 1 | 2019 | 41 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 7 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2019 | 3 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2012 | 39 | 0.040 |
Why?
|
| Acetylation | 1 | 2018 | 12 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 22 | 0.040 |
Why?
|
| Metabolomics | 1 | 2018 | 6 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 9 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 4 | 0.040 |
Why?
|
| DNA Repair | 1 | 2018 | 7 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2018 | 19 | 0.040 |
Why?
|
| HIV-1 | 1 | 2020 | 203 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 13 | 0.040 |
Why?
|
| Metabolome | 1 | 2018 | 9 | 0.040 |
Why?
|
| Reproduction | 1 | 2018 | 9 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 9 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2018 | 24 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2019 | 83 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 59 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 125 | 0.040 |
Why?
|
| Neural Stem Cells | 1 | 2018 | 9 | 0.040 |
Why?
|
| Schizophrenia | 1 | 2018 | 46 | 0.040 |
Why?
|
| Fractals | 1 | 2018 | 18 | 0.040 |
Why?
|
| Community Health Planning | 1 | 2018 | 14 | 0.030 |
Why?
|
| Pericytes | 1 | 2018 | 3 | 0.030 |
Why?
|
| Gene Library | 1 | 2018 | 7 | 0.030 |
Why?
|
| Atlases as Topic | 1 | 2018 | 6 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2018 | 14 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2015 | 550 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.030 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 88 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 12 | 0.030 |
Why?
|
| Cerebral Amyloid Angiopathy, Familial | 1 | 2017 | 1 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 5 | 0.030 |
Why?
|
| Amyloidogenic Proteins | 1 | 2017 | 1 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 33 | 0.030 |
Why?
|
| Protein Structure, Quaternary | 1 | 2017 | 5 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2017 | 9 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 18 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2017 | 4 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2017 | 10 | 0.030 |
Why?
|
| Personality Inventory | 2 | 2007 | 70 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 144 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2017 | 50 | 0.030 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 28 | 0.030 |
Why?
|
| Anisotropy | 1 | 2017 | 36 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 53 | 0.030 |
Why?
|
| Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2016 | 2 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2016 | 10 | 0.030 |
Why?
|
| Consciousness Disorders | 1 | 2016 | 5 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2016 | 3 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 16 | 0.030 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 4 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2016 | 10 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 121 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2014 | 2942 | 0.030 |
Why?
|
| Chromatin | 1 | 2016 | 14 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 52 | 0.030 |
Why?
|
| Selenium | 1 | 2016 | 6 | 0.030 |
Why?
|
| Diet Records | 1 | 2016 | 10 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cerebellum | 1 | 2016 | 34 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 139 | 0.030 |
Why?
|
| Voluntary Health Agencies | 1 | 2015 | 1 | 0.030 |
Why?
|
| Transcytosis | 1 | 2015 | 1 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 5 | 0.030 |
Why?
|
| Capillaries | 1 | 2015 | 10 | 0.030 |
Why?
|
| Pluripotent Stem Cells | 1 | 2015 | 7 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 251 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 30 | 0.030 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 45 | 0.030 |
Why?
|
| Sacrum | 1 | 2015 | 21 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 7 | 0.030 |
Why?
|
| Long-Term Potentiation | 1 | 2015 | 13 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 21 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 10 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 51 | 0.030 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2014 | 2 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 3 | 0.030 |
Why?
|
| Homeostasis | 1 | 2015 | 65 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 90 | 0.030 |
Why?
|
| Introns | 1 | 2014 | 13 | 0.030 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2014 | 6 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2014 | 6 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2014 | 6 | 0.030 |
Why?
|
| Autoantigens | 1 | 2014 | 15 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2014 | 28 | 0.030 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2014 | 1 | 0.030 |
Why?
|
| Galanin | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 24 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 2 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 21 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 12 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 88 | 0.030 |
Why?
|
| Clergy | 2 | 2005 | 72 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2014 | 79 | 0.030 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2013 | 2 | 0.030 |
Why?
|
| Circle of Willis | 1 | 2013 | 4 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 1 | 0.030 |
Why?
|
| Dextrans | 1 | 2013 | 3 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2013 | 12 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 2012 | 5 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 24 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 152 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2013 | 42 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2012 | 3 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 40 | 0.020 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2012 | 2 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 12 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 8 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 21 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cerebellar Cortex | 1 | 2012 | 6 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 143 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2012 | 45 | 0.020 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 2012 | 1 | 0.020 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Autoradiography | 1 | 2012 | 5 | 0.020 |
Why?
|
| Cadaver | 1 | 2013 | 284 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2012 | 24 | 0.020 |
Why?
|
| Glucose | 1 | 2012 | 45 | 0.020 |
Why?
|
| Cerebrovascular Trauma | 1 | 2011 | 1 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 69 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 66 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 462 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2011 | 5 | 0.020 |
Why?
|
| American Heart Association | 1 | 2011 | 15 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 21 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 45 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 4 | 0.020 |
Why?
|
| Multigene Family | 1 | 2011 | 6 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2011 | 51 | 0.020 |
Why?
|
| Parents | 1 | 2012 | 107 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2011 | 2 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2011 | 29 | 0.020 |
Why?
|
| Social Environment | 1 | 2011 | 71 | 0.020 |
Why?
|
| Phenanthrolines | 1 | 2010 | 3 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 5 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 576 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 50 | 0.020 |
Why?
|
| Neurofibrils | 1 | 2010 | 1 | 0.020 |
Why?
|
| Dendritic Spines | 1 | 2010 | 8 | 0.020 |
Why?
|
| Dendrites | 1 | 2010 | 7 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 269 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 324 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 6 | 0.020 |
Why?
|
| Fixatives | 1 | 2009 | 5 | 0.020 |
Why?
|
| Encephalitis | 1 | 2009 | 10 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2008 | 27 | 0.020 |
Why?
|
| Fatigue | 1 | 2008 | 47 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2008 | 3 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 9 | 0.020 |
Why?
|
| Subcellular Fractions | 1 | 2008 | 16 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2008 | 22 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 168 | 0.020 |
Why?
|
| Motor Neuron Disease | 1 | 2007 | 4 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 5 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Microtubules | 1 | 2007 | 26 | 0.020 |
Why?
|
| Social Isolation | 1 | 2007 | 22 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 2007 | 25 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 130 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2006 | 24 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 34 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 91 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 97 | 0.010 |
Why?
|
| Disability Evaluation | 1 | 2007 | 225 | 0.010 |
Why?
|
| Education | 1 | 2005 | 31 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 77 | 0.010 |
Why?
|